Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8
Related Questions
How will the early and deeper responses in cohort 3 affect market perception of Corvus Pharmaceuticals?
What is the expected impact of the clinically meaningful itch reduction by day 8 on future sales forecasts?
What risks remain for the drug's development despite the encouraging cohort 3 results?
What are the potential implications for Corvus' valuation and revenue projections in the next 12‑18 months?
How could the market react to the sentiment score of 65 in the context of broader sector sentiment?
How does the performance of soquelitinib in cohort 3 compare to existing atopic dermatitis treatments and competitors' pipelines?
Will the positive Phase 1 data accelerate the timeline for subsequent trial phases or regulatory submissions?
How might this data influence partnership or licensing opportunities with larger pharmaceutical companies?